Over the past two decades, antigen-directed immunotherapies like CAR-T cells, monoclonal antibodies, and bispecific T cell engagers have transformed oncology. However, their effectiveness has been limited by challenges in identifying antigens that are uniquely expressed on cancer cells, leading to off-tumor toxicity and fragmented therapeutic approaches.
Join us Thursday, January 30th where Dr. Nils Wellhausen, University of Pennsylvania, will share groundbreaking insights into the potential of epitope editing to revolutionize immunotherapies for blood cancers and HIV reservoir elimination.
In this live webinar, Dr. Wellhausen will cover:
- Targeted Immunotherapy: How epitope editing enables safe, CD45-directed CAR-T therapies for blood cancers.
- HIV Reservoir Eradication: The development of dual-edited CART45 cells to eliminate HIV-infected cells while resisting infection.
- Broad Applicability: Exploring the versatility of the CD45 platform across multiple therapeutic modalities, including BTEs.
- Advanced Editing Insights: Using the Tapestri platform to analyze editing outcomes, revealing high co-occurrence of precise edits with minimal off-target effects.
